“Elotuzumab: The First Available Immunotherapeutic Arrow Against Relapsed-Refractory Multiple Myeloma”. European Journal of Oncology and Environmental Health 22, no. 2 (November 17, 2017): 65–70. Accessed July 18, 2024. https://mattioli1885journals.com/index.php/EJOEH/article/view/6857.